The tirzepatide dose groups and regimens were as follows: 12 mg (4 mg for weeks 0-3, 8 mg for weeks 4-7, and 12 mg for weeks 8-11), 15 mg-1 (2.5 mg for weeks 0-1, 5 mg for weeks 2-3, 10 mg for weeks 4-7, and 15 mg for weeks 8-11), and 15 mg-2 (2.5 mg for weeks 0-3, 7.5 mg for weeks 4-7, and 15 mg for weeks 8-11)
[PMID: 10381186] PubMed record related to this compound for laboratory literature review
Cash-pay platforms compete on three dimensions: the medication source (FDA-approved branded vs compounded), the pricing model (all-inclusive vs membership-plus-medication), and the cancellation terms
The medication is fast tracked for approval, having received an FDA priority review voucher in November 2025
Reprod Fertil 1:6781